Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials

Cadernos de Saúde Pública

Cassyano Januário Correr¹  Inajara Rotta¹  Thaís De Souza Teles¹  Rangel Ray Godoy¹  Bruno Salgado Riveros¹  Mariana Martins Garcia¹  Patrícia Rodrigues Gonçalves¹  Michel Fleith Otuki¹ 

[1] ,Universidade Federal do ParanáCuritiba,Brasil

关键词: Psoriasis;    Biological Agents;    Efficacy;    Safety;    Health Technology Evaluation;    Psoríase;    Agentes Biológicos;    Eficácia;    Segurança;    Avaliação de Tecnologias de Saúde;    Psoriasis;    Agentes Biológicos;    Eficacia;    Seguridad;    Evaluácion de Tecnologías de Salud;   

DOI  :  10.1590/0102-311X00157013

来源: SciELO

【 摘 要 】

We conducted a systematic review and metaanalysis of randomized placebo-controlled trials in moderate-to-severe psoriasis treated with biological agents, with a follow-up of 10-14 weeks. Overall, 41 studies, with mean Jadad score of 4.4, and 15,586 patients were included. For the efficacy outcomes PASI 50, 75 and 90 our findings are not conclusive to point what biological agent has the greatest response in short term follow-up. There were no statistical differences between placebo and biologics for the occurrence of infections and serious adverse events. Ustekinumab 45mg showed lower withdrawal due to adverse events compared with the placebo. Based on data available up to now, it is not possible to determine which biological agent is the best for PASI 50, 75 or 90 after 10-14 weeks of treatment. At the same follow-up, overall safety seems to be the same for all biological agents and Ustekinumab 45mg the most well tolerated drug. To better understand efficacy and safety, indirect meta-analysis comparing drug-to-drug is required since randomized placebo-controlled trials may not be feasible.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License